U-Blot® Research Grade Setrusumab

U-Blot® Research Grade Setrusumab
U-Blot® Research Grade Setrusumab
$9,999.00
Size:50ug
SKU: WA3524-50

Catalog No.: WA3524

Specification: 50ug/100ug

Stock: In stock

Product details, specifications, documents, and related products are available from the catalog record. Learn more

10.19产品详情通用banner:Join us at JSI 2026 to explore the future of immunology! See you in Osaka!data:11.20;local:xxxxxxxxxxxxxx
Learn more

Product information

Product details, specifications, documents, and related products are available from the catalog record.

Product Overview

Catalog No.
WA3524
SKU
WA3524-50
Category
Biosimilar Antibodies
Product Type
Other
Size
50ug/100ug
Stock Status
In stock
Available Stock
999
Minimum Order Quantity
1

Storage & Compliance

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Research Use Only
Yes

Additional Specifications

PackSize
50ug/100ug
Target
SOST
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species
Human
Isotype
IgG2-lambda
Conjugate/Modification
--
Recommended Dilution Ratio
--
Composition
0.01M PBS, pH 7.4.
Purification Process
Protein A/G purified from cell culture supernatant.
Purity
>95% purity as determined by SDS-PAGE.
storageCondition
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Clonality
Monoclonal
Clone Number
--
Immunogen
Mammalian Cells
Alias
SOST, Sclerostin
Species
--
Gene ID-1
Q9BQB4
Uniprot
--
Background
Blosozumab is an IgG4-kappa type mouse monoclonal antibody optimized by humanization engineering with a molecular weight of 144.63 kDa. The monoclonal antibody was developed by Eli Lilly for the treatment of osteoporosis. Blosozumab can target and bind sclerostin (SOST) to play a biological role. In 2014, blosozumab was conducted a different doses of clinical trial about blosozumab was conducted to evaluate including drug safety, tolerance, pharmacokinetics and pharmacodynamics in postmenopausal women. The results showed that blosozumab had well tolerance and anabolic effect on bone, which could be used as a potential treatment for osteoporosis. In 2015, a randomized double-blind phase Ⅱ trial of blosozumab in postmenopausal women with low bone mineral density showed that blosozumab treatment resulted in a significant dose-dependent increase in bone mineral density, which further supports the conclusion that blosozumab is a potential anabolic therapy for osteoporosis. In September of the same year, women who had completed treatment were followed up to evaluate the effect of discontinuation of blosozumab. It was found that there were no adverse events related to the treatment one year after the cessation of treatment, and the anti-drug antibodies in the patients generally decreased.<br>• SOST/Sclerostin impairs the osteogenesis and angiogesis in glucocorticoid-associated osteonecrosis of femoral head., PMID:39342093<br/>• SOST/sclerostin, an osteocyte-derived negative regulator of bone formation., PMID:15869900<br/>• Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice., PMID:35278242<br/>• Sclerostin and Cardiovascular Disease., PMID:37490188<br/>• SOST/Sclerostin Improves Posttraumatic Osteoarthritis and Inhibits MMP2/3 Expression After Injury., PMID:29377313<br/>• Methylation of the Sclerostin <i>(SOST)</i> Gene in Serum Free DNA: A New Bone Biomarker?, PMID:33372860<br/>• Sclerostin: clinical insights in muscle-bone crosstalk., PMID:37632438<br/>• The Effects of Sclerostin on the Immune System., PMID:31970653<br/>• Sclerostin: from bench to bedside., PMID:33206222<br/>
Tissue Expression
--
Signaling_pathway
--
Research Areas
--

Tech Support

ucallm

01

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

02

Storage & Handling

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
06

Contact Support

Emailinfo@mail.ucallm.com

Phone+(1)-866-986-9598

WeChat / IMUcallm-Tech

HoursMonday-Friday 09:00-18:00 CST

Request Technical Support
Keywords:Biosimilar Antibodies